Main Download report Dansk Novozymes.com
Print Print
Audited by PwC

Statement of shareholders' equity

Statement of shareholders' equity - The Novozymes Group

  Attributable to shareholders in the company
Share capital Treasury shares Currency translations Available- for-sale financial assets Cash flow hedges Retained earnings Minority interests Total
  DKK milion DKK milion DKK milion DKK milion DKK milion DKK milion DKK milion DKK milion  
Shareholders' equity at January 1, 2005 726  (1,316) (114) 53  75  4,493  30  3,947 
Currency translation of subsidiaries and minority interests 242  245 
Fair value adjustment of financial instruments (33) (22) (48)
Cash flow hedges transferred to income statement (83) (83)
Share-based payment 15  15 
Tax relating to the above     (27)   24  57    54   
Items recognised directly in shareholders' equity     182  (81) 72  183 
Net profit           858  861   
Total income for the year     182  (81) 930  1,044 
Purchase of treasury shares (1,053) (1,053)
Sale of treasury shares 126  126 
Write-down of share capital (30) 584  (554)  
Dividend (231) (1) (232)
Other adjustments           (36) (2) (38)  
Other movements in shareholders' equity (30) (343)       (821) (3) (1,197)
Shareholders' equity at December 31, 2005 696  (1,659) 68  60  (6) 4,602  33  3,794 
The proposed dividend of DKK 256 million for 2005 is included in Retained earnings.
Reference is made to Note 18 concerning treasury shares and average number of shares.
       
   
  Attributable to shareholders in the company
Share capital Treasury shares Currency translations Available- for-sale financial assets Cash flow hedges Retained earnings Minority interests Total
  DKK milion DKK milion DKK milion DKK milion DKK milion DKK milion DKK milion DKK milion  
Shareholders' equity at December 31, 2003 754  (1,018) (158)   58  4,508  31  4,175 
IFRS impact 158  35  (212) (2) (21)
Shareholders' equity at January 1, 2004 754  (1,018)   35  58  4,296  29  4,154 
Currency translation of subsidiaries and minority interests (94) (2) (96)
Fair value adjustment of financial instruments (14) 18  83  87 
Cash flow hedges transferred to income statement (58) (58)
Share-based payment 12  12 
Tax relating to the above     (6)   (8) 63    49   
Items recognised directly in shareholders' equity     (114) 18  17  75  (2) (6)
Net profit           764  11  775   
Total income for the year     (114) 18  17  839  769 
Purchase of treasury shares (847) (847)
Sale of treasury shares 43  43 
Write-down of share capital (28) 506  (478)  
Dividend (217) (5) (222)
Purchase of minority shares (3)  
Other adjustments 50  50 
Other movements in shareholders' equity (28) (298)       (642) (8) (976)  
Shareholders' equity at December 31, 2004 726  (1,316) (114) 53  75  4,493  30  3,947 
The proposed dividend of DKK 233 milllion for 2004 is included in Retained earnings.
The reserve for currency translations has been reset at January 1, 2004 in accordance with IFRS 1.
Purchase and sale of treasury shares during the year have no significant effect on tax.
Reference is made to Note 18 concerning treasury shares and average number of shares.
© Novozymes 2006 Krogshøjvej 36 - DK-2880 Bagsværd - +45 8824 9999 - info@novozymes.com Privacy | Legal | About The Novozymes Report